Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06687234 (Dekavil) in Healthy Subjects
NCT02711462Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Feb 2016
- Primary completion
- Aug 2016
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of f8il10 in rheumatoid arthritis (RA) and ulcerative colitis (UC) (11 cohorts), sponsored by Pfizer. Primary endpoint: Number of Participants with Adverse Events (AEs) at 8 weeks. Started Feb 2016; status: terminated.
02
Drugs
f8il10
03
Conditions
rheumatoid arthritis (RA)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02711462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711462.